Clinical trials: Depressive Disorder NOS
- Condition Depressive Disorder NOS
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Major Depressive Disorder
Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®
The objective of this study is to evaluate relative bioavailability between 80 mg LY03005 oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over 2-period design under fasting condition in…
- Trial name
- NCT03357796
- Testing
- LY03005, Pristiq
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction
Trifecta Research Study
This observational study evaluates the impact of Ibogaine-Magnesium (IM), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), Magnetic e-Resonance Therapy (MeRT), and Physiological Supplementation (PS) on posttraumatic stress disorder…
- Conditions
- PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Injury, Depression - Major Depressive Disorder
- Trial name
- NCT07717866
- Testing
- Magnetic e-Resonance Therapy (MeRT), Ibogaine Hydrochloride with Magnesium Sulfate, 5-methoxy-N,N-dimethyltryptamine
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Axial Therapeutic Research
Depressive Disorder and Anxiety Disorders
First Study in Humans With GSK424887
This is the first study in Humans with GSK424887 to evaluate what effects, good or bad, the drug has on human health (safety and tolerability) and the amount of drug which gets into the bloodstream and is eliminated from the body…
- Trial name
- NCT01059591
- Testing
- GSK424887, PET
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Depressive Disorder and Anxiety Disorders
Relative Bioavailability and Food Effect Study for GSK163090 in Healthy Male and Female Volunteers
The study will consist of a screening period, 3 treatment periods and a post-treatment follow-up. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a…
- Trial name
- NCT00536679
- Testing
- GSK163090 capsule, fasted, GSK163090 Tablet, fasted, GSK163090 Tablet, fed
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder, Depression
A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression
The main goal of this clinical trial is to learn if the active study drug (code name: SP-624) has any effect on the electrical activity of the brain in adult healthy volunteers and in adults with major depression.
- Conditions
- Major Depressive Disorder, Depression, Healthy
- Trial name
- NCT06570369
- Testing
- SP-624
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sirtsei Pharmaceuticals, Inc.
Depressive Disorder, Major
Study to Evaluate the Performance Validity and Test-Retest Reliability of a Computer-Administered Cognitive Test Battery in Participants With Major Depressive Disorder (MDD)
The purpose of this study is to examine concurrent validity of 8 computerized tests intended for the assessment of cognitive function in participants with Major Depressive Disorder (MDD), relative to 8 corresponding and…
- Trial name
- NCT03014544
- Testing
- Computer- administered test battery, Examiner- administered test battery
- Where
- 20 sites in United States
- Volunteers
- 585 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Tolerability and Pharmacokinetics of Hypidone Hydrochloride in Healthy Subjects
This study will investigate the tolerability and pharmacokinetics of Hypidone Hydrochloride by multiple doses in 36 healthy male and female subjects who are of 18 to 55 years old.
- Trial name
- NCT04598607
- Testing
- Hypidone Hydrochloride tablets
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Zhejiang Huahai Pharmaceutical Co., Ltd.
Major Depressive Disorder (MDD), fNIRS
Prediction of REsponse to Depression Interventions (Accelerated rTMS) Using Clinical and TD-fNIRS Measurements
This observational, longitudinal, multi-cohort study aims to evaluate functional brain activity in adults undergoing treatment for Major Depressive Disorder (MDD) at participating clinical sites.
- Trial name
- PREDICT-ACC (NCT07294924)
- Testing
- fNIRS measurement
- Where
- 2 sites in United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Kernel
Major Depressive Disorder
A Study of LY2216684 and Digoxin in Healthy Subjects
The purpose of this study is to determine how much digoxin gets into the blood stream and how long it takes the body to get rid of it when given with LY2216684.
- Trial name
- NCT01266590
- Testing
- LY2216684, Digoxin
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder, Generalized Anxiety
Scaling Mental Healthcare in COVID-19 With Voice Biomarkers
This study aims to advance research on group sessions for mental health. The first-of-its-kind study measuring various features in a group setting, combining rich metadata in creating state-of-the-art machine learning models, and…
- Trial name
- NCT04510519
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Kintsugi Mindful Wellness, Inc.
Depression - Major Depressive Disorder, Anxiety
AcceXible Speech-Based Screening for Depression and Anxiety in University Students (BUAP, Mexico)
Major depressive disorder (MDD) and anxiety are increasingly prevalent among university student populations, yet early detection remains reliant on psychometric instruments tied to diagnostic criteria (e.g., PHQ-9, GAD).
- Trial name
- NCT07553130
- Testing
- AcceXible
- Where
- Mexico
- Volunteers
- 785 people, healthy volunteers welcome
- Sponsor
- Accexible
Major Depressive Disorder (MDD)
Validation of Accexible as a Tool for Screening and Monitoring Depression.
Major depressive disorder (MDD) is a chronic disease with a prevalence around 8-12% and is considered one of the most debilitating disease worldwide.
- Trial name
- NCT06044818
- Testing
- Accexible
- Where
- Spain
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- Accexible
Mental Disorder, Schizophrenia
A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion
The primary purpose of the study is to evaluate the positive detection accuracy (PDA) and detection latency measures of the D-Tect patch.
- Conditions
- Mental Disorder, Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
- Trial name
- NCT06372210
- Testing
- Abilify MyCite®, D-Tect Patch
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Disorder, Major
A Study of LY2216684 in Participants With Impaired Hepatic Function
The purpose of this study is to evaluate the effect of liver function on how much of the study drug (LY2216684) gets into the blood stream and how long it takes the body to get rid of it.
- Trial name
- NCT01241435
- Testing
- LY2216684
- Where
- 3 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Depressive Disorder
A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular Pressure
This study will be conducted in healthy volunteers to investigate the effect on intraocular pressure of 2 weeks of treatment with 300mg WELLBUTRIN XL/day.
- Trial name
- NCT00439868
- Testing
- WellbutrinXL
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Depression
Study Evaluating the Effects of DVS SR and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects
The purpose of this study is to evaluate the effects of multiple doses of DVS SR and paroxetine on the pharmacokinetics of a single dose of desipramine in healthy subjects.
- Trial name
- NCT00329147
- Testing
- desvenlafaxine SR, desipramine, paroxetine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder, Recurrent, Unspecified
Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005
Objectives To evaluate the safety and tolerability of escalating multiple oral doses of LY03005 in healthy subjects. To characterize the pharmacokinetics of escalating multiple oral doses of LY03005.
- Trial name
- NCT02271412
- Testing
- LY03005
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Postpartum Depression
Effect of Consuming a Combination of Probiotic Strains on Postpartum Depression
The objective of this trial is to evaluate the effect of consuming a combination of Lactobacillus during the pregnancy and lactation period on the incidence of postpartum depression.
- Trial name
- NCT06651424
- Testing
- Combination of Lactobacillus probiotics (no comercial)
- Where
- 3 sites in Spain
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Biosearch S.A.
Depressive Disorder, Major
A Study to Evaluate the Effect of Food on LY2216684
This study will evaluate the effect of food on LY2216684. There will be 2 study periods each lasting up to 5 days. There will be at least 7 days between the two doses and a follow up will occur at least 7 days after the last…
- Trial name
- NCT01389765
- Testing
- LY2216684
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Volunteers (Part 1), Major Depressive Disorder (Part 2)
Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive Disorder
This is a two part study. The objective of Part 1 is to evaluate the safety, tolerability, and pharmacokinetics of HT-2157 in healthy normal volunteers Part 2 is a randomized, double-blind, placebo-controlled, multiple (21-day)…
- Trial name
- NCT01413932
- Testing
- HT-2157
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Dart NeuroScience, LLC